KR20030028853A - The curing composition for retina injury with sulindac, and the producing method of therof - Google Patents
The curing composition for retina injury with sulindac, and the producing method of therof Download PDFInfo
- Publication number
- KR20030028853A KR20030028853A KR1020010061113A KR20010061113A KR20030028853A KR 20030028853 A KR20030028853 A KR 20030028853A KR 1020010061113 A KR1020010061113 A KR 1020010061113A KR 20010061113 A KR20010061113 A KR 20010061113A KR 20030028853 A KR20030028853 A KR 20030028853A
- Authority
- KR
- South Korea
- Prior art keywords
- chloride
- sulindac
- sodium
- pluronic
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 229960000894 sulindac Drugs 0.000 title claims abstract description 24
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 11
- 210000001525 retina Anatomy 0.000 title description 10
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 239000002904 solvent Substances 0.000 claims abstract description 37
- 230000003381 solubilizing effect Effects 0.000 claims abstract description 30
- 206010057430 Retinal injury Diseases 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- 239000003855 balanced salt solution Substances 0.000 claims abstract description 12
- 239000003889 eye drop Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920001983 poloxamer Polymers 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940013798 meclofenamate Drugs 0.000 claims abstract description 8
- -1 alkyl sodium sulfate Chemical compound 0.000 claims abstract description 7
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 229960005293 etodolac Drugs 0.000 claims abstract description 6
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002390 flurbiprofen Drugs 0.000 claims abstract description 6
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002702 piroxicam Drugs 0.000 claims abstract description 6
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000502 poloxamer Drugs 0.000 claims abstract description 6
- 230000002207 retinal effect Effects 0.000 claims abstract description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims abstract description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims abstract description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 4
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 4
- 206010046851 Uveitis Diseases 0.000 claims abstract description 4
- 230000000302 ischemic effect Effects 0.000 claims abstract description 4
- 239000001632 sodium acetate Substances 0.000 claims abstract description 4
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 229960001950 benzethonium chloride Drugs 0.000 claims description 5
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 5
- 229920001992 poloxamer 407 Polymers 0.000 claims description 5
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 claims description 3
- 229920002065 Pluronic® P 105 Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 3
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002285 methylbenzethonium chloride Drugs 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 206010056677 Nerve degeneration Diseases 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 abstract description 4
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012792 core layer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000005606 carbostyryl group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 설린닥을 활성성분으로 함유하는 망막손상 치료용 안약 조성물과 그 제조방법에 관한 것이다.The present invention relates to an ophthalmic composition for treating retinal injury, which contains sulindac as an active ingredient, and a method of manufacturing the same.
망막 질환 치료를 위한 여러 가지 약물치료 방법들이 사용되거나 개발되고있다.Various drug treatment methods for the treatment of retinal diseases are used or developed.
예를 들어, 망막 퇴화를 억제하는 신경영양인자(neurotrophic factor)가 있으나, 치료제로서의 가격이 비싼 단점이 있다.For example, there is a neurotrophic factor that inhibits retinal degeneration, but there is a disadvantage that the price as a therapeutic agent is expensive.
또한, 망막 신경질환 치료를 위한 여러 약물치료 방법들이 있으나, 그 중에 안구의 초자체강(vitreous body)내로 약물을 주입하는 방법은 손상 부위에 직접 주사하여 효과가 높지만, 여러 번 주사할 경우 망막에 손상을 준다.In addition, there are several drug treatment methods for the treatment of retinal nerve disease. Among them, the method of injecting the drug into the vitreous body of the eye is highly effective by injecting directly into the injured area. Gives.
혈관 주사는 투여가 쉽고, 반복투여하기도 좋지만 손상부위 까지 약물을 전달시키려면 다량이 약물이 필요하다.Vascular injections are easy to administer and may be repeated, but large amounts of drug are required to deliver the drug to the damaged area.
먹는 방법은 약물 투여 중 가장 쉽지만, 흡수된 약물은 간에서 생체 대사를 거친 후 손상된 조직에 전달되므로 좋은 효과를 기대하기 어렵다.Eating is the easiest method of drug administration, but absorbed drugs are metabolized in the liver and then delivered to damaged tissues, so it is difficult to expect good effects.
이러한 이유로 최근에는 안약을 이용한 치료방법들이 개발되고 있다.For this reason, treatment methods using eye drops have recently been developed.
한국특허출원 10-1998-0702671(PCT/JP1996/02850)(안과 질환 질환 치료용 카르보스티릴 유도체) 에는 카르보스티릴 유도체를 유효성분으로 하는 안과질환 치료제가 공지되어있으나, 본원발명의 안약 조성물과는 활성성분과 조성이 다르고, 목적과 효과가 상이하다.Korean Patent Application No. 10-1998-0702671 (PCT / JP1996 / 02850) (carbostyryl derivative for the treatment of ophthalmic diseases) is known ophthalmic disease therapeutic agent containing the carbostyryl derivative as an active ingredient, Is different from the active ingredient and has a different purpose and effect.
또한, 한국특허출원 10-2000-7008301(PCT/JP1999/00369)(안약 조성물)에 특정 화합물 또는 알도오스 환원효소 억제제를 활성성분으로 포함함을 특징으로 하여 당뇨성 각막장애의 치료 및 각막 감각 저하의 치료에 사용되는 안약 조성물이 공지되어 있으나, 본원발명의 안약 조성물과는 활성성분이 다르고, 목적과 효과가 다르다.In addition, Korean Patent Application No. 10-2000-7008301 (PCT / JP1999 / 00369) (eye drops composition) comprises a specific compound or aldose reductase inhibitor as an active ingredient, characterized in that the treatment of diabetic corneal disorders Ophthalmic compositions for use in the treatment of the known are known, but the active ingredient is different from the ophthalmic composition of the present invention, the purpose and effect are different.
한편, 비스테로이드성 염증 치료제로 사용되고 있는 약제인 설피린(Sulpyrin), 피록시캠(Piroxicam), 에토돌락(Etodolac), 플루비프로펜(Flurbiprofen), 메클로페나메이트(Meclofenamate), 설린닥(Sulindac) 등은 물에 난용성이어서 이들에 대한 적정한 가용화 용매의 개발이 필요한 실정이다.Meanwhile, Sulpyrin, Piroxicam, Etodolac, Flurbiprofen, Meclofenamate, and Sullyndak, which are used as drugs for treating nonsteroidal inflammation, Sulindac) and the like are poorly soluble in water, it is necessary to develop an appropriate solubilizing solvent for them.
물에 난용성인 설린닥을 DMSO나 알코올과 같은 유기용매를 사용하여 가용화 할 경우, 인체에 투여 시 부작용이 있어 적합하지 못하다.If solubilizing solubility in water using an organic solvent such as DMSO or alcohol, there is a side effect when administered to the human body is not suitable.
상기한 바와 같이, 망막을 보호하고 망막손상을 치료하는 새롭고 효과적인 활성 성분과 그 것을 가용화 하는 용매를 이용한 새로운 안약의 개발이 요청되고 있다.As mentioned above, there is a need for the development of new eye drops using new and effective active ingredients that protect the retina and treat retinal damage and solubilizing the same.
본 발명은 상기와 같은 문제점을 해결하기 위해, 새로운 활성성분과 가용화 용매를 개발하고, 약물 투여가 쉬우며 반복 투여가 가능하고 간 대사를 거치지 않고 약물을 표적 부위까지 전달할 수 있는, 새로운 망막 손상 치료용 안약 조성물과 그 제조방법을 제공하는데 목적이 있다.In order to solve the above problems, the present invention develops a new active ingredient and a solubilizing solvent, is easy to administer the drug, it is possible to repeat the administration and treatment of new retinal damage, which can deliver the drug to the target site without liver metabolism An object of the present invention is to provide an ophthalmic composition and its preparation method.
도 1은 본 발명의 가용화용매S와, 설린닥을 활성성분으로 함유하는 안약 조성물의 제조공정도1 is a manufacturing process diagram of a solubilizing solvent S of the present invention, and an ophthalmic composition containing Sullak as an active ingredient.
도 2는 본 발명의 설린닥을 활성성분으로 함유하는 안약 조성물 투여에 의한 망막 손상 보호효과 사진Figure 2 is a photograph of the protective effect of retinal damage by the administration of an ophthalmic composition containing the sulindac of the present invention as an active ingredient
도 3은 본 발명의 설린닥을 활성성분으로 함유하는 안약 조성물의 망막 손상 보호효과의 정량적 분석도Figure 3 is a quantitative analysis of the retinal damage protection effect of the ophthalmic composition containing the sulindac of the present invention as an active ingredient
본 발명은, 난용성인 설린닥(Sulindac) 등을 용해하는 가용화용매S와, 설린닥(Sulindac, 이하 SLD를 병기함)을 활성 성분으로 함유하는 망막 손상 치료용 안약 조성물과 그 제조방법에 관한 것이다.The present invention relates to a solubilizing solvent S that dissolves insoluble Sullindac and the like, an ophthalmic composition for treating retinal damage, and a method for preparing the retinal injury, which contains Sulindac (hereinafter referred to as SLD) as an active ingredient. .
또한, 본 발명은 비스테로이드성 염증 치료에 쓰이고 있으나 난용성인 설피린(Sulpyrin), 피록시캠(Piroxicam), 에토돌락(Etodolac), 플루비프로펜(Flurbiprofen), 메클로페나메이트(Meclofenamate), 설린닥(Sulindac) 등의 가용화 용매로도 사용될 수 있는 가용화용매S에 관한 것이다.In addition, the present invention is used in the treatment of non-steroidal inflammation, but poorly soluble Sulpyrin (Pulpyrin), Piroxicam, Etodolac (Etodolac), Flurbiprofen (Flurbiprofen), Meclofenamate (Meclofenamate), It relates to a solubilizing solvent S that can also be used as a solubilizing solvent such as Sulindac.
증류수에 염화나트륨, 초산나트륨 등을 녹여 균형염용액(Balanced salt solution)을 제조하고, 여기에 폴록사머(Poloxamer), 소디움 올레이트(Sadium oleate), 벤즈알코니움 클로라이드(Benzalconium chloride) 등에서 선택된 1종 또는 2종의 계면활성제를 5 ~ 20 %(w/w) 용해하여 가용화용매S를 제조한 다음, 가용화용매S의 pH를 5 ~ 8.5로 조정하여 안점적용매를 제조하고, 여기에 활성 성분으로 설린닥을 0.1 ~ 2 mg/ml의 비율로 용해시켜 본 발명의 설린닥을 활성성분으로 함유하는 망막 손상 치료용 안약 조성물을 제조한다.Dissolve sodium chloride and sodium acetate in distilled water to make balanced salt solution, and select one of them from poloxamer, sodium oleate, and benzalconium chloride. Or dissolving two surfactants in 5 to 20% (w / w) to prepare a solubilizing solvent S, and then adjusting the pH of the solubilizing solvent S to 5 to 8.5 to prepare a eye drop solvent. Sullydac is dissolved at a rate of 0.1 to 2 mg / ml to prepare an ophthalmic composition for treating retinal injury, which contains the sulfinac of the present invention as an active ingredient.
아래 화학식 1 로 나타낸 설린닥(Sulindac)은 공지의 물질로서, 비스테로이드성 염증치료제로서 대장염 및 장염의 치료에 사용되고 있다.Sulindac (Sulindac) represented by the following formula (1) is a known substance, and is used for the treatment of colitis and enteritis as a nonsteroidal inflammatory agent.
<화학식 1><Formula 1>
본 발명자들은 상기의 설린닥이 망막 질환 치료제로서 높은 효과를 나타냄을 발견하고 여러 차례의 실험을 거쳐 본 발명을 완성하게 되었다.The present inventors have found that the above-mentioned sulfindac exhibits a high effect as a therapeutic agent for retinal disease, and has been completed the present invention through several experiments.
본 발명의 설린닥을 활성 성분으로 함유하는 망막손상 치료용 안약 조성물은 녹내장과 당뇨병성 망막증에 의한 허혈성 망막손상과 포도막염에 의한 망막 신경의 퇴화 등의 치료에 사용된다.The ophthalmic composition for treating retinal injury, which contains the sulfinac of the present invention as an active ingredient, is used for the treatment of ischemic retinal injury due to glaucoma and diabetic retinopathy, and degeneration of the retinal nerve due to uveitis.
한편, 안약을 이용하여 망막의 퇴화를 막고, 손상된 망막의 치료를 위해서는, 약물이 망막까지 전달되어 효과를 나타내야 하므로 약물을 전달시키는 용매가 중요하며, 약물의 안정성 또한 중요하다.On the other hand, to prevent degeneration of the retina by using the eye drops, and for the treatment of the damaged retina, because the drug must be delivered to the retina to have an effect, the solvent for delivering the drug is important, the stability of the drug is also important.
설린닥은 난용성으로 DMSO나 알코올과 같은 유기용매를 사용하여 가용화 시킬 경우, 인체에 투여 시 부작용이 있어 적합하지 못하다.Sullindak is poorly soluble and solubilized using an organic solvent such as DMSO or alcohol, which is not suitable because of side effects when administered to the human body.
본 발명자들은 적정 용매를 찾기 위해 여러 차례의 반복실험을 한 결과, 계면활성제인 폴록사머(Poloxamer) 등을 이용한 가용화용매를 만들어 내고, 이것을 가용화용매S 라고 명명하였다.The present inventors conducted a number of repeated experiments in order to find a suitable solvent to produce a solubilizing solvent using a poloxamer (surfactant), such as a solubilizing solvent S.
폴록사머는 폴리에틸렌 옥시드-폴리프로필렌옥시드-폴리에틸렌 옥시드의 트리블록 코폴리머(triblock copolymer)이다.Poloxamers are triblock copolymers of polyethylene oxide-polypropyleneoxide-polyethylene oxide.
본 발명의 가용화용매S는 난용성인 설피린(Sulpyrin), 피록시캠(Piroxicam), 에토돌락(Etodolac), 플루비프로펜(Flurbiprofen), 메클로페나메이트(Meclofenamate), 설린닥(Sulindac) 등의 가용화 용매로도 사용된다.The solubilizing solvent S of the present invention is a poorly soluble sulfyrin (Sulpyrin), Piroxicam (Piroxicam), Etodolac (Flurbiprofen), Meclofenamate (Meclofenamate), Sulindac (Sulindac), etc. It is also used as a solubilizing solvent.
본 발명의 가용화용매S와 설린닥을 활성성분으로 함유하는 망막손상 치료용 안약 조성물의 제조과정을 도 1을 참조하여 설명한다.The manufacturing process of the ophthalmic composition for treating retinal injury, containing the solubilizing solvent S and sulindac of the present invention as an active ingredient, will be described with reference to FIG.
먼저 균형염용액(balanced salt solution)을 제조한다.First, a balanced salt solution is prepared.
멸균된 증류수 100 ml에 염화나트륨(sodium chloride) 640 mg, 염화칼륨(potassium chloride) 75 mg, 염화칼슘(calcium chloride) 48 mg, 염화마그네슘(magnesium chloride) 30 mg, 초산나트륨(hydrochloric acid) 390 mg, 구연산 나트륨(citric acid) 170 mg의 비율로 녹여서 균형염용액을 제조한다.In 100 ml of sterilized distilled water, 640 mg of sodium chloride, 75 mg of potassium chloride, 48 mg of calcium chloride, 30 mg of magnesium chloride, 390 mg of hydrochloric acid, sodium citrate (citric acid) Dissolve at a rate of 170 mg to make a balanced salt solution.
한편, 균형염용액은 알콘(Alcon)사, 또는 삼일제약의 제품을 구매하여 사용할 수도 있다.Meanwhile, the balanced salt solution may be used by purchasing a product of Alcon, or Samil Pharmaceutical.
또한, 균형염용액 제조시 사용되는 각 조성 성분들은 일정 범위내에서 같은 활성을 나타내는 다른 화합물로 치환하거나, 그 조성 비율을 달리 할 수도 있다.In addition, each of the components used in the preparation of the balanced salt solution may be substituted with other compounds exhibiting the same activity within a certain range, or the composition ratio thereof may be varied.
균형염 용액에 계면활성제로 중성인 폴록사머, 음이온성인 알킬소디움설페이트, 양이온성인 벤제토니움클로라이드 등에서 선택된 1 종 또는 2 종을 5 ~ 20 % (w/w)가하여 가용화용매S를 제조한다.Solubilizing solvent S is prepared by adding 5-20% (w / w) of one or two selected from neutral poloxamer, anionic alkylsodium sulfate, and cationic benzethonium chloride as a surfactant to the balanced salt solution.
이 때 사용하는 중성 물질인 폴록사머(poloxamaer : poly(ethylene oxide) -poly(propylene oxide)-poly(ethylene oxide) triblock copolymer)로는 플루로닉(pluronic)F68, 플루로닉 F127, 플루로닉 P105, 플루로닉 L44 등에서 선택하여 사용한다.At this time, as a neutral material, poloxamaer (poly (ethylene oxide) -poly (propylene oxide) -poly (ethylene oxide) triblock copolymer), Pluronic F68, Pluronic F127, Pluronic P105 And Pluronic L44.
음이온성 물질로는 알킬소디움설페이트(alkyl sodium sulfate), 소디움로릴설페이트(sodium lauryl sulfate), 디옥틸소디움설포숙시네이트( dioctyl sodium sulfosuccinate), 소디움올레이트(sodium oleate) 등에서 선택하여 사용한다.The anionic material is selected from alkyl sodium sulfate, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, sodium oleate, and the like.
양이온성 물질로는 벤제토니움클로라이드(benzethonium chloride), 벤즈알코니움클로라이드(benzalkonium chloride), 메틸벤제토니움클로라이드(methylbenzethonium chloride), 세틸피리디니움클로라이드( cetylpyridinium chloride) 등에서 선택하여 사용한다.As the cationic material, benzethonium chloride, benzalkonium chloride, benzalkonium chloride, methylbenzethonium chloride, cetylpyridinium chloride and the like are used.
가용화용매S의 pH를 조정하여 안점적용매(eye drop solution solvent)를 제조한다.The pH of the solubilizing solvent S is adjusted to prepare an eye drop solution solvent.
KCl, NaCl, Tris-HCl, K2HPO4, KH2PO4, Na2HPO4, NaH2PO4, NaHCO3, NaBO4, (NH4)2CO3, 글리신(glycine), NaOH에서 선택된 하나 또는 2 개 이상을 조합하여 pH를 3 ∼ 9, 바람직하게는 pH를 5 ~ 8.5 로 조정한 안점적용매를 제조한다.Selected from KCl, NaCl, Tris-HCl, K 2 HPO 4 , KH 2 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 , NaHCO 3 , NaBO 4 , (NH 4 ) 2 CO 3 , glycine, NaOH One or two or more are combined to prepare an eye drop solvent having a pH of 3 to 9, preferably a pH of 5 to 8.5.
안점적용매에 설린닥을 0.01 ∼ 10 mg/ml로, 바람직하게는 0.1 ~ 2 mg/ml 의 농도로 용해시켜 본 발명의 설린닥을 활성성분으로 함유하는 망막손상 치료용 안약조성물을 제조한다.Sullydac is dissolved in an eye drop solvent at a concentration of 0.01 to 10 mg / ml, preferably 0.1 to 2 mg / ml to prepare an ophthalmic composition for treating retinal injury, which contains the sulfinac of the present invention as an active ingredient.
이하 실시예 및 실험예를 들어 본 발명을 상세히 설명하나, 이들이 본 발명의 내용을 한정하는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples, but these examples do not limit the content of the present invention.
<실시예 1> 가용화용매S 의 제조Example 1 Preparation of Solubilized Solvent S
설린닥을 가용하는데 사용하는 가용화용매S를 도 1과 같이 제조하였다.A solubilizing solvent S used to solubilize sullindac was prepared as shown in FIG.
멸균된 증류수 100ml에 염화나트륨(sodium chloride) 640mg, 염화칼륨(potassium chloride) 75mg, 염화칼슘(calcium chloride) 48mg, 염화마그네슘(magnesium chloride) 30mg, 초산나트륨(hydrochloric acid) 390mg, 구연산 나트륨(citric acid) 170mg을 녹여서 균형염용액을 만들었다.In 100 ml of sterilized distilled water, 640 mg of sodium chloride, 75 mg of potassium chloride, 48 mg of calcium chloride, 30 mg of magnesium chloride, 390 mg of hydrochloric acid, and 170 mg of citric acid It melted to make a balanced salt solution.
이 때 , pH는 7.4, 삼투압은 305 mOsm/kg 였다.At this time, pH was 7.4 and osmotic pressure was 305 mOsm / kg.
균형염용액에 플루로닉(Pluronic) F127을 150 ml 녹였다.150 ml of Pluronic F127 was dissolved in a balanced salt solution.
플루로닉 F127이 완전히 녹아서 용액이 맑아졌다.Pluronic F127 was completely dissolved and the solution was clear.
여기에 벤즈알코니움 클로라이드(benzalkonium chloride)를 0.15 ㎖를 녹여 본 발명의 가용화용매S를 제조하였다.Here, solubilizing solvent S of the present invention was prepared by dissolving benzalkonium chloride in 0.15 ml.
<실시예 2> 설린닥을 활성성분으로 함유하는 망막 손상 치료용 안약 조성물의 제조<Example 2> Preparation of an ophthalmic composition for treating retinal injury containing sulindac as an active ingredient
실시예 1에서 제조한 가용화용매S의 pH를 측정하였다.The pH of the solubilizing solvent S prepared in Example 1 was measured.
pH 측정치가 7.2 였으므로 별도의 pH 조절과정은 생략하고, 이것을 안점적용매(eye drop solution solvent)로 사용했다.Since pH measurement was 7.2, a separate pH adjustment process was omitted and this was used as an eye drop solution solvent.
안점적용매에 설린닥 150 mg을 4℃에서 녹여, 본 발명의 설린닥을 활성성분으로 함유하는 망막손상 치료용 안약 조성물을 제조하였다.150 mg of sullindac in an eye drop solvent was dissolved at 4 ° C. to prepare an ophthalmic composition for treating retinal injury, which contains sullindac of the present invention as an active ingredient.
제조된 안약 조성물을 실온에서 보관 후 HPLC로 안정성을 확인한 결과 3 개월 이상 안정하였다.After storing the prepared ophthalmic composition at room temperature and confirmed the stability by HPLC, it was stable for more than 3 months.
<실험예 1> 본 발명의 설린닥을 활성성분으로 함유하는 망막손상 치료용 안약 조성물의 망막 보호효과 실험<Experimental Example 1> Experimental retinal protective effect of the ophthalmic composition for the treatment of retinal injury containing sulindac of the present invention as an active ingredient
수컷 흰쥐(Sprague Dawley, 8 주령, 300 g)를 실험동물로 사용하였다.Male rats (Sprague Dawley, 8 weeks old, 300 g) were used as experimental animals.
롬푼(rompun)과 케탈라(ketala)를 1:2의 비율로 섞어 1 ml/kg으로 근육 주사하여 마취하였다.Rompun and ketala were mixed at a ratio of 1: 2 and anesthetized by intramuscular injection at 1 ml / kg.
압력계가 달린 가압기를 이용하여 안구 전방내의 압력을 160 mmHg로 올려 망막으로 흐르는 혈액을 1시간 동안 차단하여 망막 허혈을 유도하였다.The pressure inside the eyeball was increased to 160 mmHg using a pressure gauge with a pressure gauge to block the blood flowing to the retina for 1 hour to induce retinal ischemia.
실시예 2에서 제조한 안약 조성물을 허혈을 유도한 흰쥐의 눈에 50㎕/drop 씩 2 방울을 20 분마다 2 시간 동안 직접 투여하였다.The ophthalmic composition prepared in Example 2 was directly administered to the eyes of rats induced ischemia with 2 drops of 50 μl / drop for 2 hours every 20 minutes.
최종 투여 24 시간 후에 안구를 적출하고 망막을 분리한 다음, 2.5 % 글루타르알데하이드(glutaraldehyde)에 고정하고 포스페이트 버퍼(phosphate buffer)로 세척하였다.After 24 hours of final administration, the eye was taken out and the retina was separated, fixed in 2.5% glutaraldehyde and washed with phosphate buffer.
알콜 농도 상승 순으로 탈수한 다음 프로필렌 옥사이드(propylene oxide)로 치환하고 에폰 믹스추어(epon mixture)에 포매하였다.After dehydration in the order of increasing alcohol concentration, it was substituted with propylene oxide and embedded in an epon mixture.
포매된 조직을 1 ㎛의 조직절편으로 만들어 톨루이딘 블루(toluidine blue)로 염색한 다음, 광학현미경 하에서 망막 퇴화 및 보호효과를 관찰하였다.Embedded tissue was made into 1 μm tissue sections and stained with toluidine blue, and then the retinal degeneration and protective effect were observed under an optical microscope.
그 결과를 도 2에 나타냈다.The result is shown in FIG.
도 2와 같이 허혈로 손상된 망막에서는 신경절세포층에서 세포의 손실이 관찰되고, 내핵층에서는 응축되어 검은 점으로 보이는 죽는 세포들이 관찰되었다.As shown in FIG. 2, cell loss was observed in the ganglion cell layer in the ischemia-damaged retina, and dying cells appearing as black dots condensed in the inner nuclear layer.
그러나, 본 발명의 설린닥을 함유하는 안약 조성물이 투여된 망막의 신경절 세포층과 내핵층에서 정상에 비하여 70 % 정도의 세포가 더 남아 있었고, 내핵층에서는 응축되어 퇴화되는 세포가 줄어들어 있었다.However, in the ganglion cell layer and the inner core layer of the retina to which the ophthalmic composition containing the sulfinac of the present invention was administered, about 70% of cells remained more than normal, and in the inner core layer, cells condensed and degraded were reduced.
<실험예 2> 본 발명의 설린닥을 활성성분으로 함유하는 안약 조성물의 망막 손상 보호효과의 정량적 분석Experimental Example 2 Quantitative Analysis of Retinal Damage Protection Effect of Ophthalmic Compositions Containing Suldinak of the Present Invention
실험예 1의 각각의 조직표본을 만든 다음, 광학현미경하에서 망막내의 각 층에서 100 X 100 ㎛ 범위 안에서 살아 있는 세포 수를 세고, 정상과 비교하여 %로 나타내었다.Each tissue specimen of Experimental Example 1 was made, and the number of viable cells was counted in the range of 100 X 100 μm in each layer in the retina under an optical microscope and expressed in% compared to normal.
측정된 수치는 통계분석을 위하여 student T-test로 분석하여(p < 0.05) 그 결과를 도 3과 표 1에 나타냈다.The measured value was analyzed by the student T-test for statistical analysis (p <0.05) and the results are shown in Figure 3 and Table 1.
Non은 설린닥이 없는 버퍼(buffer)만 투여된 대조군이다.Non is a control group administered only buffer without sulfadoc.
<표 1 > 본 발명의 설린닥을 함유하는 안약 조성물의 투여 효과TABLE 1 Administration effect of the ophthalmic composition containing sulfindag of the present invention
신경절세포층에서 대조군의 59.61 %에 비해 SLD 투여군 70.46 %, 내핵층에서대조군 65.38 %에 비해 SLD 투여군 83.97 % 였다.In ganglion cell layer, SLD-treated group was 70.46% compared with 59.61% of control group and SLD-treated group 83.97% compared to control group 65.38% in inner core layer.
본 발명에 의해, 난용성인 약제를 가용화 하는 가용화용매S 가 제공되고, 또한 설린닥(Sulindac)을 활성성분으로 함유하는 망막손상 치료용 안약 조성물과 그 제조방법이 제공되며, 본 발명의 안약 조성물은, 녹내장과 당뇨병성 망막증에 의한 허혈성 망막손상과 포도막염에 의한 망막 신경의 퇴화 등의 치료에 사용된다.According to the present invention, there is provided a solubilizing solvent S solubilizing a poorly soluble drug, and also provides an ophthalmic composition for treating retinal injury and a method for producing the same, which contain Sulindac as an active ingredient. It is used for the treatment of ischemic retinal damage caused by glaucoma and diabetic retinopathy and degeneration of retinal nerve by uveitis.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0061113A KR100430428B1 (en) | 2001-10-04 | 2001-10-04 | The curing composition for retina injury with sulindac, and the producing method of therof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0061113A KR100430428B1 (en) | 2001-10-04 | 2001-10-04 | The curing composition for retina injury with sulindac, and the producing method of therof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030028853A true KR20030028853A (en) | 2003-04-11 |
| KR100430428B1 KR100430428B1 (en) | 2004-05-04 |
Family
ID=29563192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2001-0061113A KR100430428B1 (en) | 2001-10-04 | 2001-10-04 | The curing composition for retina injury with sulindac, and the producing method of therof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100430428B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049014A1 (en) * | 2003-11-18 | 2005-06-02 | Pharmacia Corporation | Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders |
| KR100682341B1 (en) * | 2004-02-26 | 2007-02-15 | 주식회사 오케이컨설턴트 | Rehabilitation structure of bridge beam by using of a combined saddle and middle fixation braket |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101305721B1 (en) | 2011-12-27 | 2013-09-06 | 가톨릭대학교 산학협력단 | New formulation of sulindac for inhibiting angiogenesis and neo-lymphangiogenesis, and ophthalmic composition comprising the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4402979A (en) * | 1980-03-21 | 1983-09-06 | Merck & Co., Inc. & Laboratories | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid |
| US4307114A (en) * | 1980-06-19 | 1981-12-22 | Ayerst, Mckenna & Harrison, Inc. | Aldose reductase inhibition by (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid |
| KR100451087B1 (en) * | 1997-01-30 | 2005-08-18 | 김종국 | New Flubipropene Emulsion Injection Composition |
| US20010006965A1 (en) * | 1998-04-17 | 2001-07-05 | Rifat Pamukcu | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols |
-
2001
- 2001-10-04 KR KR10-2001-0061113A patent/KR100430428B1/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049014A1 (en) * | 2003-11-18 | 2005-06-02 | Pharmacia Corporation | Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders |
| KR100682341B1 (en) * | 2004-02-26 | 2007-02-15 | 주식회사 오케이컨설턴트 | Rehabilitation structure of bridge beam by using of a combined saddle and middle fixation braket |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100430428B1 (en) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5110493A (en) | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant | |
| US10398725B2 (en) | Ophthalmic compositions and methods of use | |
| NL192821C (en) | Ophthalmic solution. | |
| US7875271B2 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
| JP6359217B2 (en) | Novel iodophor composition and method of use | |
| KR20010012521A (en) | Antiseptic composition | |
| JP2011093923A (en) | Ophthalmic solution | |
| KR101934767B1 (en) | Novel ophthalmic composition and methods of use | |
| GR1009040B (en) | Preservative free pharmaceutical ophthalmic compositions | |
| KR100430428B1 (en) | The curing composition for retina injury with sulindac, and the producing method of therof | |
| US20230338540A1 (en) | Xanthan-based ophthalmic topical formulations with a reduced dosage regimen | |
| WO2019135779A1 (en) | Novel ophthalmic composition and methods of use | |
| CA3088185C (en) | Suspension compositions of multi-target inhibitors | |
| CN115867264A (en) | Topical ophthalmic compositions and methods for treating abnormal angiogenesis | |
| CA2817505C (en) | Pharmaceutical formulation having neuroprotective activity | |
| US20180200289A1 (en) | Novel ophthalmic composition and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| N231 | Notification of change of applicant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130411 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20140212 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160425 Year of fee payment: 13 |
|
| LAPS | Lapse due to unpaid annual fee |